Microsoft Corporation (NASDAQ:MSFT) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. TD Cowen Keeps Buy on Microsoft (MSFT) Despite Softer Azure Growth Pixabay/Public Domain On January 29, TD Cowen trimmed its price recommendation on Microsoft Corporation (NASDAQ:MSFT) to $610 from $625. It kept a Buy rating on the stock. The firm pointed to softer Azure growth, though guidance held up. Demand continues to exceed supply, forcing Microsoft to carefully manage capacity across first-party inference, internal R&D, and Azure services. The latest quarter showed why expectations remain high. Microsoft posted $81.3 billion in revenue, up 17% year over year and nearly $1 billion ahead of forecasts. Earnings per share came in at $4.14, up 24% and $0.22 above estimates. Net income stood out, jumping 60% to $38.5 billion. Margins dipped slightly as spending increased, but cash generation remains strong. Xbox Content and Services was the only segment to post a decline, down 5% for the quarter. One number that keeps coming up in conversations is backlog. Microsoft now has $625 billion in future contracted revenue. That figure usually signals strength, but there is a wrinkle. About $281 billion of that backlog is tied to OpenAI. Cloud services are not like digital platforms, where capacity scales easily. Every new Azure customer requires real infrastructure, real power, and real space. Right now, Microsoft is running into limits. Demand is ahead of available capacity, which helps explain the large backlog. It is a good problem in one sense, though it does place a ceiling on how fast Azure can grow in the near term. Even so, Azure revenue still rose 39% in the quarter. Growth may cool from here, but at Microsoft’s scale, that pace remains meaningful. Microsoft Corporation (NASDAQ:MSFT) develops and supports software, services, devices, and technology solutions across enterprise, consumer, and cloud markets. While we acknowledge the potential of MSFT as an inves...

Microsoft Corporation (NASDAQ:MSFT) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. TD Cowen Keeps Buy on Microsoft (MSFT) Despite Softer Azure Growth Pixabay/Public Domain On January 29, TD Cowen trimmed its price recommendation on Microsoft Corporation (NASDAQ:MSFT) to $610 from $625. It kept a Buy rating on the stock. The firm pointed to softer Azure growth, though guidance held up. Demand continues to exceed supply, forcing Microsoft to carefully manage capacity across first-party inference, internal R&D, and Azure services. The latest quarter showed why expectations remain high. Microsoft posted $81.3 billion in revenue, up 17% year over year and nearly $1 billion ahead of forecasts. Earnings per share came in at $4.14, up 24% and $0.22 above estimates. Net income stood out, jumping 60% to $38.5 billion. Margins dipped slightly as spending increased, but cash generation remains strong. Xbox Content and Services was the only segment to post a decline, down 5% for the quarter. One number that keeps coming up in conversations is backlog. Microsoft now has $625 billion in future contracted revenue. That figure usually signals strength, but there is a wrinkle. About $281 billion of that backlog is tied to OpenAI. Cloud services are not like digital platforms, where capacity scales easily. Every new Azure customer requires real infrastructure, real power, and real space. Right now, Microsoft is running into limits. Demand is ahead of available capacity, which helps explain the large backlog. It is a good problem in one sense, though it does place a ceiling on how fast Azure can grow in the near term. Even so, Azure revenue still rose 39% in the quarter. Growth may cool from here, but at Microsoft’s scale, that pace remains meaningful. Microsoft Corporation (NASDAQ:MSFT) develops and supports software, services, devices, and technology solutions across enterprise, consumer, and cloud markets. While we acknowledge the potential of MSFT as an inves...

格隆汇2月6日｜据知情人士透露，英国石油(BP.N)正在寻找合作伙伴，以帮助提升位于中东地区一处最古老油田的产量，并共同分担部分成本。知情人士称，伊拉克基尔库克油田的潜在投资者寻觅工作已经在进行中。任何协议的达成时间尚不确定，其中一人表示，预计这一过程将持续到明年。大型石油公司正重新对伊拉克表现出浓厚兴趣。伊拉克拥有丰富的原油资源，其开采过程往往比中东以外的地区更为简便且成本更低。与此同时，英国石油公司正寻求在石油和天然气生产领域实现更多国际增长，从而放弃了此前五年对清洁能源和净零排放的追求。

AMD Confirms Steam Machine Ships Early 2026 as Next Xbox SoC Readies for 2027 Launch extremetech.com

Earnings Call Insights: Qiagen N.V. (QGEN) Q4 2025 Management View Thierry Bernard, CEO, stated that "QIAGEN continued to perform and delivered a solid finish to '25 with results in the fourth quarter, again above outlook." Bernard highlighted that net sales were $540 million in the fourth quarter, growing 1% at CER, while adjusted diluted EPS reached $0.62 at constant exchange rates, both exceeding the company’s outlook. For the full year, net sales were $2.09 billion, up 5% at CER, and adjusted diluted EPS increased to $2.40 at CER. Bernard emphasized, "across our growth pillars, Sample technologies, QuantiFERON, QIAstat, QIAcuity and QIAGEN Digital Insights, they all achieved combined sales of $1.49 billion at CER in '25, delivering 8% growth at CER again." He also noted the completed acquisition of Parse Biosciences, which extended sample technologies into single cell analysis. Bernard reflected on operational improvements: "For 2025, our adjusted operating income margin increased 80 basis points to 29.5%, reflecting continued efficiency gains across the business." Free cash flow was $453 million, supporting business investment and shareholder capital returns, including more than $1.1 billion returned since 2024 and the introduction of an annual dividend. Bernard announced a Supervisory Board change: Mark Stevenson joined in January, while Ross Levine stepped down but will continue as Chair of the Scientific Advisory Board. Roland Sackers, CFO, stated, "We delivered solid results with sales for '25 at the high end of our outlook with continued strength in consumables and our growth pillars amid a cautious funding and capital spending environment." Sackers also emphasized margin expansion and disciplined capital deployment, referencing the $500 million share repurchase completed in January 2026. Outlook Sackers provided 2026 guidance: "For the full year '26, we are initiating an outlook for sales growth of at least 5 percentage points CER and adjusted earnings pe...

Earnings Call Insights: Tradeweb Markets Inc. (TW) Q4 2025 Management View CEO William Hult highlighted that Tradeweb achieved its best revenue year and quarter in company history, surpassing $2 billion in annual revenue for the first time. Hult stated, "Our 2025 performance continues our seventh consecutive year as a public company, producing double-digit revenue growth and the 26th consecutive year of record annual revenues." He emphasized strong momentum in electronic trading expansion, particularly in areas previously dominated by manual processes, and noted significant advances in digital asset infrastructure, stating, "We have made significant strides alongside our key partners in moving digital assets from something built on a whiteboard to a real advancement in market infrastructure." Hult reported that "rates produced a record revenue quarter, driven by continued organic growth across swaps, global government bonds and mortgages," and that money markets revenue growth was propelled by record revenues in global repos. The CEO also pointed to nearly 10% growth in equities, over 90% growth in other revenues due to scaling digital asset initiatives, and strong international expansion, with Asian client revenues up over 35% and European client revenues up over 25%. Hult stated that Tradeweb completed the first ever fully electronic bilateral swaptions and U.S. multi-asset package trade across the swaps market, launched the first electronic platform for Saudi Royal bonds and Mexican repos, and achieved record market share in electronic institutional U.S. treasuries. CFO Sara Furber reported, "this quarter, we saw record revenues of $521 million that were up 12.5% year-over-year on a reported basis." Furber added, "We earned $6.6 million from our commercial relationship with the Canton network from our role as a Super Validator on the network, where we are compensated in Canton Coins." She also noted, "2025 annual adjusted EBITDA margin of 54% increased by 64 basi...

Earnings Call Insights: NetScout Systems, Inc. (NTCT) Q3 2026 Management View Anil Singhal, Co-Founder, Chairman, President & CEO, stated that "our third quarter fiscal year 2026 revenue and earnings results were ahead of expectations. These results were enhanced by certain product orders and service renewal that had been anticipated for the fourth quarter as customers use their remaining calendar year-end budgets." He highlighted that growth was seen across both Cybersecurity and Service Assurance offerings, and announced an increase in the midpoint of the company's top and bottom line outlook for fiscal year 2026. Singhal emphasized product innovation, mentioning the "recently released Omnis AI sensor and AI streamer" and the upcoming "nGenius Edge Sensor 795," which reflect NETSCOUT's expansion in remote site observability and next-generation WiFi. The CEO highlighted industry recognition, including awards for the Omnis Cyber Intelligence platform and NETSCOUT's position as Frost & Sullivan's 2025 Global Company of the Year in network monitoring. Notable customer wins were cited, including a "mid-7-figure order in our Service Assurance area from a new customer within the insurance industry" and "two additional mid- to high 7-figure deals in Europe with existing customers" for Cybersecurity solutions. Anthony Piazza, Executive VP & CFO, stated, "total revenue for the third quarter was $250.7 million, which was relatively consistent with the same period last year at $252 million and ahead of our outlook provided last quarter." Outlook NETSCOUT raised the midpoint of its fiscal year 2026 revenue and non-GAAP earnings per share outlook ranges. Revenue is now expected to be in the range of $835 million to $870 million, representing 3.6% year-over-year growth at the midpoint. Non-GAAP earnings per diluted share are forecasted between $2.37 and $2.45. Piazza commented, "This outlook reflects our solid execution, the continued demand for our solutions and the resilience ...

It won't happen overnight, but patience goes a long way. When it comes to retirement savings, the $1 million mark has long been a major milestone for most people. How far that takes you in retirement is a different story, but there's something about hitting the seven-figure mark that feels like a bit of financial freedom. The good news is that reaching $1 million doesn't require luck or getting in early on the next big thing. It can be accomplished with time and consistency. If you're currently around the $100,000 mark, here are three things you can do to potentially 10x it to $1 million. 1. Start as early as possible This might seem like "well, of course" type of advice, but I've noticed that people often underestimate just how powerful time can be in investing, thanks to compound earnings. It's the gift that keeps on giving and one of the keys to building wealth in the stock market. To see it in action, let's imagine you invest $100,000 in a stock or exchange-traded fund (ETF) that averages 10% annual returns. Below is how much your investment would grow to over different amounts of time: Years Invested Investment Value 10 $259,300 15 $417,700 20 $672,000 25 $1.08 million 30 $1.74 million In this scenario, the difference between giving yourself 20 years versus 15 years is over $254,000. The difference between 30 and 25 years is around $660,000. The more time you give yourself, the more it pays off. 2. Invest in dividend stocks Since stock price movements get a lot of attention, many people don't realize how much dividends can contribute to a stock's total gains. Over the past 20 years, the S&P 500 has averaged 8.8% annual returns. When you include dividends, the average goes up to 10.9%. If a one-time $100,000 investment were made back then, the 2.1% difference would equal more than a $250,000 difference in investment value. Even investing in a dividend ETF like the Schwab U.S. Dividend Equity ETF can be lucrative. It has a 3.5% average dividend yield over the pas...

rafal_olechowski Ginkgo Bioworks Holdings ( DNA ) announced on Thursday that, in collaboration with Microsoft ( MSFT )-backed OpenAI ( OPENAI ), it has designed an AI system that can lower costs in cell-free protein synthesis by 40%. Unlike DNA-based protein synthesis, cell-free protein synthesis can rapidly produce proteins without the need for living cells, making it useful for scientists who require quick clinical results. The findings detailed in a scientific preprint that has yet to undergo peer review suggest that the system conducted more than 36,000 CFPS reactions across 580 automated plates, generating nearly 150,000 experimental data points. The cell platform company added that the partnership combined OpenAI's ( OPENAI ) GPT-5 large language model with Ginkgo's ( DNA ) cloud laboratory infrastructure. "By pairing a frontier large language model with an autonomous lab, we found reaction compositions that are notably cheaper than the prior state of the art," Ginkgo co-founder and co-author of the study, Reshma Shetty, said. "At OpenAI, this was the first time we were able to interface a frontier model with an autonomous lab to carry out experimentation at a very large scale," added Joy Jiao, the study’s co-corresponding author and life sciences research lead at OpenAI. More on Ginkgo Bioworks Holdings, Microsoft, etc. Microsoft: Rampant Selloff A Case Of Market Disconnect And Irrational 'SaaSapocalypse' Fears Microsoft: It Is Just A Dip, Not A Bargain Meta Beats Microsoft At AI Monetization - Here's Why The software sector goes through a ‘forest fire’ every 10-15 years, markets are ‘about to take off’ – analyst ‘We’re going to look back at this selloff as a table pounder time to own names' – Wedbush’s Dan Ives

Most of the buildings at the University of Massachusetts were constructed in the 1950s and the 1960s, and the signs of aging are clear, President Marty Meehan says. When it rains, roofs leak. And even during harsh New England winters, students crack windows open to air out stuffy dorm rooms. But UMass is poised for a facelift, and so are other public schools and community colleges across the state, thanks to a so-called millionaire tax that will authorize $3.65 billion in campus renovations. If passed, Massachusetts Governor Maura Healey ’s BRIGHT Act will issue 10-year special obligation bonds to finance the fixes. The securities would be backed by revenue from the Fair Share Amendment , a 4% levy on taxable incomes over $1 million. The bill — An Act to Build Resilient Infrastructure to Generate Higher Education Transformation – cleared the state’s House of Representatives in November and awaits action in the upper chamber, where Senator Jo Comerford expects it to pass. She chairs the Joint Committee on Higher Education and was a member of the working group that came up with the plan to modernize higher education facilities in Massachusetts. “We heard that schools needed a systemic solution to a systemic problem,” Comerford said in an interview. “These buildings are owned by the Commonwealth, and we want to keep tuition and fees as low as possible. That means we have to lift the capital burden off campuses.” Enrollment Impacts Outdated dormitories and classrooms are a big problem at UMass, Meehan said in an interview. The system has identified up to $4.8 billion in potential upgrades across its five campuses, an endeavor that would take 10 years to complete. Falling behind on renovations can drive away potential students, a serious risk for most colleges in the Northeast as the pool of prospective students in the region is expected to shrink by 17% by 2041. Read More: Too Many Colleges, Too Few Kids: Birth Rate Drop Hits US Schools “In order to attract students, we...

Image source: The Motley Fool. Friday, August 1, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Board Co-Chair, Co-Founder, President, and Chief Executive Officer — Leonard S. Schleifer Board Co-Chair, Co-Founder, President, and Chief Scientific Officer — George D. Yancopoulos Executive Vice President, Commercial — Marion E. McCourt Executive Vice President and Chief Financial Officer — Christopher R. Fenimore Senior Vice President, Investor Relations — Ryan Crowe TAKEAWAYS Total Revenues -- $3.7 billion, up 4%, reflecting growth from Dupixent, EYLEA HD, and Libtayo collaborations. -- $3.7 billion, up 4%, reflecting growth from Dupixent, EYLEA HD, and Libtayo collaborations. Diluted Net Income per Share -- $12.89, an increase of 12%, with net income reaching $1.4 billion. -- $12.89, an increase of 12%, with net income reaching $1.4 billion. Dupixent Global Net Product Sales -- $4.3 billion, representing 21% growth on a constant currency basis, driven by expansion across all approved indications, age groups, and geographies. -- $4.3 billion, representing 21% growth on a constant currency basis, driven by expansion across all approved indications, age groups, and geographies. U.S. Dupixent Net Product Sales -- $3.2 billion, up 23%, consolidating leadership in new-to-brand prescriptions for seven of eight FDA-approved indications. -- $3.2 billion, up 23%, consolidating leadership in new-to-brand prescriptions for seven of eight FDA-approved indications. Libtayo Global Net Product Sales -- $377 million, a 25% increase on a constant currency basis, now annualizing at $1.5 billion. -- $377 million, a 25% increase on a constant currency basis, now annualizing at $1.5 billion. Libtayo U.S. Net Product Sales -- $248 million, up 36%, benefiting from timing of approximately $20 million in customer shipments (expected to adversely impact next quarter). -- $248 million, up 36%, benefiting from timing of approximately $20 million in customer shipments (expected to adversely impact next q...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Things haven’t been pleasant for Microsoft (MSFT) investors over the last couple of years, as the company underperformed Big Tech peers in both 2024 and 2025. This year is looking no better, and MSFT stock is down around 17% for the year. In absolute terms, the stock, which peaked around $555 last year, is now close to $400 price levels, and its market cap is around $3 trillion. Microsoft’s woes intensified after the company released its earnings for the December quarter last week. While the company beat on headline numbers, the report got a thumbs down from markets, and MSFT stock plunged by nearly 10%, eroding over $350 billion in market cap in a single day. Following the fiscal Q2 2026 earnings report, several analysts lowered their target prices, but the stock’s mean target price is still above $600 and represents a potential upside of around 50% from these levels. Let's explore whether MSFT stock can rise above $600 over the next year, as many sell-side analysts seem to believe, or if it is headed for another dismal year. We'll begin with an overview of its earnings. Why Microsoft’s Fiscal Q2 Earnings Spooked Investors The Satya Nadella-led company beat on both the top line and the bottom line in the December quarter. However, its earnings still spooked markets for more than one reason. These include: AI Spending Spree : Like fellow Big Tech peers, Microsoft is doubling down on artificial intelligence (AI) spending, and its capex was $37.5 billion in the quarter, of which two-thirds are short-lived assets. For context, the quarterly capex was more than the annual capex in fiscal year 2023. There are lingering concerns over tech companies’ ability to adequately monetize these investments, which are draining their cash flows. Specifically, Microsoft’s free cash flows fell to $5.9 billion in the quarter. : Like fellow Big Tech peers, Microsoft is doubling down on artificial intelligence (AI) spending, and its capex was $37.5 billion in the quarter, of which two-th...

Could Microsoft Stock Hit $600 in 2026 Despite OpenAI Woes? Yahoo Finance

人物．故事｜醫人醫心．冼維正 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】冼維正習醫的年代，醫學院並沒有專為深切治療（ICU）而設的專科訓練，早期的ICU亦側重生理醫治和儀器應用等。他於2001年港大醫學院內外全科醫學士畢業後服務瑪麗醫院，後來加入ICU歇力拯救垂危病人。2020年冼維正重返母校執教，兩年後出任深切治療醫學部首任總監，除了對危重症進行臨床診治及醫學研究，亦關顧家屬的需要及「後ICU」病人癒後的身心情況。他關注人文科學，重視病人自主意願，並藉此向社會推動生死教育，期望提升公眾對預設醫療指示及臨終關懷等認識。

Image source: The Motley Fool. Tuesday, Feb. 4, 2025 at 8:30 a.m. ET Call participants Board Co-Chair, Co-Founder, President, and Chief Executive Officer — Dr. Leonard Schleifer Board Co-Chair, Co-Founder, President, and Chief Scientific Officer — Dr. George Yancopoulos Executive Vice President, Commercial — Marion McCourt Executive Vice President and Chief Financial Officer — Chris Fenimore Vice President, Investor Relations and Strategic Finance — Ryan Crowe Takeaways Total revenues -- $3.8 billion for the quarter, up 10% year over year, reflecting higher Dupixent collaboration revenue, strong Libtayo growth, and modest growth from combined EYLEA HD and EYLEA net sales in the U.S. -- $3.8 billion for the quarter, up 10% year over year, reflecting higher Dupixent collaboration revenue, strong Libtayo growth, and modest growth from combined EYLEA HD and EYLEA net sales in the U.S. Diluted net income per share -- $12.07 in the quarter, representing $1.4 billion in net income, up 2% from the prior year. -- $12.07 in the quarter, representing $1.4 billion in net income, up 2% from the prior year. Full-year revenue (excluding Ronapreve) -- $14.2 billion, a 10% increase compared to the prior year. -- $14.2 billion, a 10% increase compared to the prior year. Full-year earnings per share -- $45.62, increasing 4% year over year. -- $45.62, increasing 4% year over year. Sanofi collaboration revenue -- $1.2 billion in the quarter, with $1 billion from Regeneron's share of collaboration profits, representing an 18% increase year over year due to Dupixent volume and higher margins. -- $1.2 billion in the quarter, with $1 billion from Regeneron's share of collaboration profits, representing an 18% increase year over year due to Dupixent volume and higher margins. Bayer collaboration -- Ex-U.S. EYLEA and EYLEA 8 mg net sales were $888 million, up 2% on a constant currency basis, with $377 million in total collaboration revenue. -- Ex-U.S. EYLEA and EYLEA 8 mg net sales were $888 ...

Canada Goose Holdings Inc. ’s Canadian shares are on pace for the worst decline in over six years after the luxury parka maker missed on key earnings metrics despite a frigid winter season. The Toronto-listed stock fell as much as 24% on Thursday, marking the retailer’s biggest intraday decline since May 2019, before paring some of the losses. US-listed shares of the company sank as much as 21%. The fiscal third-quarter results “will likely trim earnings per share expectations for 2026 and beyond,” Bloomberg Intelligence analysts Andrea Ferdinando Leggieri and Deborah Aitken wrote. Canada Goose reported an adjusted earnings before interest and taxes margin of 29.3% in the third quarter, falling short of the 32.9% forecast by analysts, according to data compiled by Bloomberg. “The miss is despite one of the best winters ever,” BNP Paribas analyst Laurent Vasilescu wrote in a note to clients. In 2019, Canada Goose lost over a quarter of its market value after reporting its first-ever revenue miss, which raised concerns at the time that the company’s soaring growth was hitting the brakes. At the time, the 31% drop had been its worst performance since the company’s public debut in 2017.

Nvidia Could Delay New GPU Due To Deepening Memory Crunch News flow around the memory crunch is accelerating by the week , and the casualty list is growing. Just this morning, Qualcomm and Arm Holdings warned that shortages of high-bandwidth memory (HBM) could crimp smartphone production this year. Apple signaled earlier this week that it will prioritize higher-end iPhone models, while Nintendo shares slid as soaring HBM costs threaten to squeeze margins. The alarm bells are getting louder after a new report from The Information , citing two sources, saying Nvidia won't release a new gaming GPU ( RTX 60 series) this year due to a HBM supply crunch , forcing it to prioritize limited HBM for its far more profitable AI chips over gaming GPUs. If confirmed, it would mark the first year in roughly three decades that Nvidia has not released a new consumer-grade gaming GPU . Here's more color from The Information: The delay will also push back the release of Nvidia's next-generation gaming GPU. Likely called the RTX 60 series, it was originally scheduled to begin mass production at the end of 2027, according to one of th people. The existing line of gaming GPUs, the RTX 50, is based on Nvidia's current Blackwell GPUs , while the RTX 60 is based on the upcoming Rubin chips. Nvidia CEO Jensen Huang publicly announced last month that mass production of Rubin AI chips had already started and that the company was on track to ship them to customers in the second half of this year. . . . Nvidia is also slashing production of its current line of gaming chips —the GeForce RTX 50 GPUs—because of the memory shortage, one of the people said. Prices of Nvidia's latest gaming GPUs have already risen at retail stores and websites due to their scarcity over the past year. "Demand for GeForce RTX GPUs is strong, and memory supply is constrained," a Nvidia spokesperson told the tech outlet, without confirming the delay. The person added that all GeForce products are in stock and shipping to...

Image source: The Motley Fool. Oct. 31, 2024 at 8:30 a.m. ET CALL PARTICIPANTS Board Co-Chair, Co-Founder, President, and Chief Executive Officer — Dr. Leonard Schleifer Board Co-Chair, Co-Founder, President, and Chief Scientific Officer — Dr. George Yancopoulos Executive Vice President of Commercial — Marion McCourt Senior Vice President and Chief Financial Officer — Chris Fenimore Vice President, Investor Relations — Ryan Crowe TAKEAWAYS Total Revenue -- $3.72 billion, up 11%, primarily driven by higher Sanofi collaboration revenue, growth in Libtayo, and combined EYLEA HD and EYLEA performance in the United States. -- $3.72 billion, up 11%, primarily driven by higher Sanofi collaboration revenue, growth in Libtayo, and combined EYLEA HD and EYLEA performance in the United States. Dupixent Global Revenue -- $3.8 billion, increasing 24% on a constant currency basis, with over 1 million patients treated across 7 approved indications. -- $3.8 billion, increasing 24% on a constant currency basis, with over 1 million patients treated across 7 approved indications. Dupixent Recent Label Expansions -- FDA and regulators in China approved Dupixent for uncontrolled COPD with an eosinophilic phenotype; European approval was granted in June. -- FDA and regulators in China approved Dupixent for uncontrolled COPD with an eosinophilic phenotype; European approval was granted in June. EYLEA HD and EYLEA US Net Sales -- $1.54 billion, a 3% year-over-year increase; EYLEA HD contributed $392 million, growing 29% sequentially, while combined product share in the anti-VEGF category was approximately 44%. -- $1.54 billion, a 3% year-over-year increase; EYLEA HD contributed $392 million, growing 29% sequentially, while combined product share in the anti-VEGF category was approximately 44%. EYLEA HD Clinical Update -- Photon extension study data showed that after one year on EYLEA HD, 83% of switched patients maintained a dosing interval of at least 12 weeks, and nearly half of baseline...

格隆汇2月6日｜美国白宫：（就古巴问题）特朗普始终乐于开展外交活动。

格隆汇2月6日｜美国白宫：古巴政府已岌岌可危。

格隆汇2月6日｜美国白宫：美国将继续与俄罗斯商讨新的协议事宜。

格隆汇2月6日｜美国白宫：相信古巴政府正在发生某些事情。

Barclays has reportedly cut ties with the lobbying firm co-founded by Peter Mandelson, after intense scrutiny of the founders’ dealings with the late child sex offender Jeffrey Epstein. Vodafone has also said it is reviewing its contract for public affairs services with Global Counsel, which Mandelson co-founded in 2010 after Labour lost the general election. Mandelson has tried to distance himself from the lobbying firm after the revelations of the extent of his relationship with Epstein sparked a major political scandal. Mandelson resigned from the Labour party on Sunday. The former minister was sacked as ambassador to the US in September after the emergence of emails that suggested he had a close relationship with Epstein, who died in prison in 2019 while awaiting trial over child sex-trafficking charges. The further allegation that Mandelson leaked sensitive information on government policy to Epstein has triggered a political crisis for the UK prime minister, Keir Starmer. The newly released emails from the US Department of Justice investigation have also put Global Counsel under intense scrutiny. The Financial Times reported that Barclays had dropped the firm due to frustration over its handling of Mandelson’s remaining stake, citing a person close to the situation. Vodafone said its “current one-year contract ends in March” and “no decisions have been taken regarding its renewal”, the FT reported. Barclays and Vodafone were approached for comment. Rokos Capital Management, a £16bn London hedge fund, on Thursday said it had “terminated” talks with Mandelson over an advisory role after revelations of the government leaks. The Epstein files appeared to show that Mandelson regularly shared information about his efforts to start Global Counsel with Epstein. He also shared emails on his other business dealings, such as seeking the lucrative role of chair at the mining company Glencore. Mandelson did not secure that job, but Global Counsel did win business providing...

NYC Comptroller Mark Levine Calls for Oversight of Palantir’s Involvement with the Department of Homeland Security and U.S. Immigration and Customs Enforcement NYC.gov

格隆汇2月6日｜壳牌(SHEL.N)公司首席执行官表示，由于哈萨克斯坦对石油巨头提起的诉讼涉及金额可能高达数十亿美元，公司将暂停在哈萨克斯坦的投资。据悉，哈萨克斯坦正通过该国法院及国际仲裁机构，就多起案件向多家西方石油公司追索赔偿。本月披露的壳牌及其合作伙伴败诉案中，涉案赔偿金额可能高达40亿美元。此外，关于硫排放超标及项目成本的诉讼仍在进行中。壳牌首席执行官称：“这确实影响了我们进一步在哈萨克斯坦投资的意愿。”尽管该公司认为未来存在大量投资机会，但“我们会等到有更清晰的判断后再做决定。”

Image source: The Motley Fool. Thursday, Oct. 30, 2025 at 8 a.m. ET Call participants President & CEO — Christophe Weber Chief Financial Officer — Milano Furuta President, R&D — Andrew Plump President, Global Oncology Business Unit — Teresa Bitetti Head, Global Portfolio Division & CEO Elect — Julie Kim Chief Medical Officer, Global Oncology R&D — Phuong (P.K.) Morrow President, Plasma-Derived Therapies Business Unit — Giles Platford Chief Strategy Officer — Christopher David O'Reilly Takeaways Revenue -- Just over JPY 2.2 trillion, representing a 6.9% decrease, or a 3.9% decrease at constant exchange rates, primarily due to the loss of exclusivity for VYVANSE. -- Just over JPY 2.2 trillion, representing a 6.9% decrease, or a 3.9% decrease at constant exchange rates, primarily due to the loss of exclusivity for VYVANSE. Core operating profit -- JPY 639.2 billion, down 11.2% (actual FX) and 8.8% at constant exchange rates, with approximately one-third of the year-on-year decline attributable to transactional foreign exchange effects. -- JPY 639.2 billion, down 11.2% (actual FX) and 8.8% at constant exchange rates, with approximately one-third of the year-on-year decline attributable to transactional foreign exchange effects. Reported operating profit -- JPY 253.6 billion, a 27.7% decrease driven chiefly by a JPY 58.2 billion impairment from discontinuing cell therapy efforts. -- JPY 253.6 billion, a 27.7% decrease driven chiefly by a JPY 58.2 billion impairment from discontinuing cell therapy efforts. Net profit/EPS -- Reported net profit and EPS both declined by 40%, reflecting the non-tax-deductible cell therapy impairment. -- Reported net profit and EPS both declined by 40%, reflecting the non-tax-deductible cell therapy impairment. Adjusted free cash flow -- JPY 525.4 billion, benefiting from improvements in working capital. -- JPY 525.4 billion, benefiting from improvements in working capital. Growth and launch products -- Portfolio contributed over 50% of reven...

文章提及标的 原油 -- 美原油 -- WTI原油期货价格收跌2.84%，报63.29美元/桶。(财联社)

Earnings Call Insights: Cummins Inc. (CMI) Q4 2025 Management View CEO Jennifer Rumsey stated that "we delivered strong financial performance despite weak demand in North America truck markets, ongoing trade tariff volatility and an uncertain regulatory landscape." She highlighted the introduction of the X10 engine within the Cummins HELM platforms, replacing both the L9 and X12 platforms, and the unveiling of the B7.2 diesel engine, designed as a global platform to serve various applications. Rumsey emphasized the acquisition of First Mode and a collaboration with Komatsu to accelerate hybrid solutions in mining, as well as the launch of the S17 Centum generator set targeting urban power needs. She noted, "we initiated a review of our electrolyzer business within the Accelera segment to streamline operations and focus investments amid policy-driven shifts in hydrogen demand." Actions taken led to recorded charges in Q4 aimed at lowering costs moving forward. CFO Mark Smith stated, "we delivered strong operational results in 2025, achieving record EBITDA and earnings per share, excluding onetime items despite the down cycle in North America truck markets and ongoing tariff volatility." Smith detailed that Q4 revenues were $8.5 billion with EBITDA of $1.2 billion or 13.5% of sales, including $218 million in charges related to the Accelera electrolyzer business. Excluding these, EBITDA reached $1.4 billion or 16%. He added, "Power Systems delivered a record full year EBITDA of 22.7% of sales, up from 18.4% in 2024. While Distribution achieved a record 14.6% of sales, up from 12.1% in the prior year." Outlook Rumsey projected total company revenues for 2026 to be up 3% to 8% compared to 2025 and EBITDA, including the impact of tariffs, to be 17% to 18% of sales. She commented that North America heavy and medium-duty truck demand is expected to be weak in the first half but improve in the second half, with industry production for heavy-duty trucks in North America proje...

格隆汇2月6日｜美国白宫：（当被问及是否与俄罗斯就新削减战略武器条约达成了临时协议时）据我们所知，并没有。美国总统特朗普希望让我们的核专家着手制定一项全新的、经改进的且现代化的条约。